Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to -$544000.0.

  • Zevra Therapeutics' Consolidated Net Income rose 9836.27% to -$544000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $35.3 million, marking a year-over-year increase of 13939.71%. This contributed to the annual value of -$105.5 million for FY2024, which is 12912.77% down from last year.
  • As of Q3 2025, Zevra Therapeutics' Consolidated Net Income stood at -$544000.0, which was up 9836.27% from $74.7 million recorded in Q2 2025.
  • Zevra Therapeutics' 5-year Consolidated Net Income high stood at $74.7 million for Q2 2025, and its period low was -$35.7 million during Q4 2024.
  • For the 5-year period, Zevra Therapeutics' Consolidated Net Income averaged around -$5.6 million, with its median value being -$10.3 million (2021).
  • Its Consolidated Net Income has fluctuated over the past 5 years, first surged by 62211.87% in 2021, then plummeted by 67438.79% in 2024.
  • Zevra Therapeutics' Consolidated Net Income (Quarter) stood at -$2.7 million in 2021, then soared by 368.41% to $7.3 million in 2022, then plummeted by 374.18% to -$19.9 million in 2023, then plummeted by 79.67% to -$35.7 million in 2024, then surged by 98.48% to -$544000.0 in 2025.
  • Its last three reported values are -$544000.0 in Q3 2025, $74.7 million for Q2 2025, and -$3.1 million during Q1 2025.